Deepkamal N. Karelia

Deepkamal N. Karelia

Auto-generated profile, based on publicly available information

Deepkamal N. Karelia

Department of Pharmacology Pennsylvania State University College of Medicine Hershey Pennsylvania USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Plano DanielPlano Daniel
Plano Daniel
DKDeepkamal N. Karelia
Deepkamal N. Karelia
MPManoj K. Pandey
Manoj K. Pandey
JSJulian E. Spallholz
Julian E. Spallholz
SAShantu Amin
Shantu Amin
Arun SharmaArun Sharma
Arun Sharma

1 May 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VAVeronica Alcolea
Veronica Alcolea
Plano DanielPlano Daniel
Plano Daniel
DKDeepkamal N. Karelia
Deepkamal N. Karelia
JPJuan Antonio Palop
Juan Antonio Palop
SAShantu Amin
Shantu Amin
Arun SharmaArun Sharma
Arun Sharma

1 June 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VKVinod Kumar
Vinod Kumar
KKKamalneet Kaur
Kamalneet Kaur
DKDeepkamal N. Karelia
Deepkamal N. Karelia
VBVikas Beniwal
Vikas Beniwal
GGGirish Kumar Gupta
Girish Kumar Gupta
AGAkhilesh Kumar Gupta
Akhilesh Kumar Gupta

25 February 2016 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MPManoj Pandey
Manoj Pandey
Sahdeo PrasadSahdeo Prasad
Sahdeo Prasad
ATAmit Tyagi
Amit Tyagi
LDLokesh Deb
Lokesh Deb
JHJiamin Huang
Jiamin Huang
BABharat B. Aggarwal
Bharat B. Aggarwal
Escaping from cell death is one of the adaptations that enable cancer cells to stave off anticancer therapies. The key players in avoiding apoptosis are collectively known as survival proteins. Survival proteins comprise the Bcl-2, inhibitor of apoptosis (IAP), and heat shock protein (HSP) families. The aberrant expression of these proteins is associated with a range of biological activities that promote cancer cell survival, proliferation, and resistance to therapy. Several therapeutic strategies that target survival proteins are based on mimicking BH3 domains or the IAP-binding motif or competing with ATP for the Hsp90 ATP-binding pocket. Alternative strategies, including use of nutraceuticals, transcriptional repression, and antisense oligonucleotides, provide options to target survival proteins. This review focuses on the role of survival proteins in chemoresistance and current therapeutic strategies in preclinical or clinical trials that target survival protein signaling pathways. Recent approaches to target survival proteins-including nutraceuticals, small-molecule inhibitors, peptides, and Bcl-2-specific mimetic are explored. Therapeutic inventions targeting survival proteins are promising strategies to inhibit cancer cell survival and chemoresistance. However, complete eradication of resistance is a distant dream. For a successful clinical outcome, pretreatment with novel survival protein inhibitors alone or in combination with conventional therapies holds great promise.

25 September 2016
Verified
Book Chapter
Closed access
PDF file
MPManoj Pandey
Manoj Pandey
DKDeepkamal Karelia
Deepkamal Karelia
SAShantu G. Amin
Shantu G. Amin

1 July 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DKDeepkamal N. Karelia
Deepkamal N. Karelia
USUgir Hossain Sk
Ugir Hossain Sk
PSParvesh Singh
Parvesh Singh
AGA.S. Prakasha Gowda
A.S. Prakasha Gowda
MPManoj K. Pandey
Manoj K. Pandey
Arun SharmaArun Sharma
Arun Sharma